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OBJECTIVES The purpose of this study was to determine whether carvedilol’s alpha1-adrenoceptor
antagonism persists during long-term therapy of patients with congestive heart failure
(CHF).
BACKGROUND Carvedilol and metoprolol differ in that carvedilol also antagonizes beta2- and alpha1-
adrenoceptors. We hypothesized that in contrast to metoprolol, carvedilol would increase calf
vascular conductance (CVC), blunt neurally mediated vasoconstriction and attenuate neu-
roeffector transfer function gain.
METHODS We randomized 36 patients with CHF (age 55 1 years, ejection fraction 19 1%, means
SE) to either drug. Blood pressure (BP), heart rate, muscle sympathetic nerve activity
(MSNA) and CVC were assessed before and after four months of treatment. The variability
of BP and MSNA was determined using fast Fourier transformation.
RESULTS Paired data were obtained in 23 (carvedilol, 13; metoprolol, 10) subjects. Both beta-blockers
decreased heart rate, but neither affected mean BP or CVC (carvedilol: 0.016  0.002 to
0.018  0.003 U; metoprolol: 0.020  0.002 to 0.020  0.004 U). Isometric handgrip
exercise (30% of maximum) increased heart rate, mean BP and MSNA. The calf vasocon-
strictor response to handgrip exercise was not affected by carvedilol (from 16 6 resistance U
to 25 10 resistance U, NS). The gain of the transfer of oscillations in MSNA into BP under
resting conditions was not attenuated by carvedilol.
CONCLUSIONS Carvedilol did not increase CVC, blunt the calf vasoconstrictor response to handgrip or
attenuate the gain of the neuroeffector transfer function, indicating the absence of functionally
important peripheral alpha1-adrenoceptor antagonism during long-term treatment of CHF.
(J Am Coll Cardiol 2001;38:1463–9) © 2001 by the American College of Cardiology
Sympathetic nervous system activation is a well-characterized
marker of adverse prognosis in patients with congestive
heart failure (CHF) (1–3). Placebo-controlled trials of
carvedilol, which blocks beta2- and alpha1- as well as
beta1-adrenoceptors, provided the first definitive evidence
for mortality reduction with beta-blockade (4–8). However,
the selective antagonists, metoprolol and bisoprolol, were
subsequently also shown to improve outcome (9,10), sug-
gesting that beta1-antagonism may be the primary mecha-
nism by which this benefit is achieved. Whether the beta2-,
and alpha1-antagonistic properties of carvedilol, or its anti-
oxidant action, confer any therapeutic advantage beyond
that of beta1-selective agents is currently the subject of a
large randomized clinical trial (11). However, in a recent
trial, bucindolol, another nonselective beta-antagonist, did
not show mortality benefit compared with a placebo control
(12), and in a prospective study metoprolol and carvedilol
had similar effects on an indirect marker of oxidative stress
(13). These negative findings have redirected attention at
the potential benefits of concomitant alpha1-blockade.
Whether carvedilol’s alpha1-adrenoceptor antagonism
persists during long-term therapy and contributes to its
effects on hemodynamics is unclear. Some investigators
report a reduction in systemic vascular resistance with
chronic treatment (14,15), but this has not been a consistent
finding (16,17). Symptomatic orthostatic hypotension can
occur when carvedilol is introduced, but this usually sub-
sides with time. Regional circulatory responses to neuro-
genic vasoconstrictor stimuli have not been reported.
The objective of this study was to determine whether
significant alpha1-adrenoceptor blockade could be detected
in patients with chronic stable CHF after four months of
carvedilol. We applied both time and frequency domain
analysis to compare the effects of carvedilol and metoprolol
on blood pressure (BP), muscle sympathetic nerve activity
(MSNA) and calf vascular conductance (CVC). We hy-
pothesized, first, that carvedilol, by blocking alpha1-
receptors, would increase resting CVC. To exclude with-
drawal of efferent sympathetic vasoconstrictor discharge as a
cause of local vasodilation during long-term treatment,
MSNA was measured simultaneously in the opposite leg
(18,19). Our second hypothesis was that carvedilol would
blunt alpha1-mediated neurogenic vasoconstriction induced
by handgrip exercise. Finally, we hypothesized that carve-
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dilol, by blocking the postjunctional action of neurally
released norepinephrine at the level of the alpha1-receptor,
would blunt the BP response to changes in sympathetic
outflow, as evidenced by a decrease in the gain of the
transfer function between the variability of MSNA and the
variability of BP, as an index of neuroeffector transduction
(20).
METHODS
Subjects. Patients with stable CHF secondary to ischemic
heart disease or idiopathic cardiomyopathy were recruited.
Inclusion criteria included symptoms (New York Heart
Association functional class II or class III), stable medical
therapy for 1 month, documented systolic ventricular
dysfunction with a left ventricular ejection fraction 35%
and no prior exposure to beta-blockade. Exclusion criteria
included peripheral neuropathy, an acute coronary syn-
drome within three months, primary valvular heart disease,
contraindications to beta-blockade, systolic BP 85 mm Hg
and resting heart rate 60 beats/min. This study was one
aspect of a larger protocol approved by the University of
Toronto Human Subjects Review Committee. Informed,
written consent was obtained from all participants.
Procedures. All studies were performed in the same quiet,
temperature-controlled room at the same time of the day.
Subjects rested supine. In a subgroup, maximal voluntary
contraction was predetermined using a handgrip dynamom-
eter (right arm) (Lafayette Instrument, model 78010,
Lafayette, Indiana). Blood pressure was measured each
minute from the right arm by an automatic cuff recorder
(Critikon, Dinamap 1846 SX, Johnson and Johnson,
Tampa, Florida) and also continuously from a left finger
(Ohmeda 2300 Finapres, Englewood, Colorado) to permit
power spectral analysis. Heart rate was derived from lead II
of the electrocardiogram (ECG). Blood flow in the left calf
(CBF) (ml/min/100 ml of calf volume) was estimated by
venous occlusion plethysmography (Hokanson, Bellevue,
Washington). The MSNA was recorded from the right
peroneal nerve (18,19).
Protocol. After instrumentation, subjects lay quietly for
15 min to achieve steady state. The ECG, MSNA and the
Finapres BP signals were then recorded continuously onto
paper and by computer over a 9-min baseline period (20).
The CBF was determined every 20 s over the last 2 min of
baseline. In 18 subjects, there was a further 5-min rest
period, then 2 min of prehandgrip recording followed by
2 min of isometric exercise at 30% of maximal voluntary
contraction. This protocol was replicated after four months
of beta-blockade.
After the first experimental session, patients were ran-
domized in a double-blind fashion to receive either carve-
dilol or metoprolol tartrate, in addition to their previous
treatment. Those allocated to carvedilol received an initial
dose of 3.125 mg twice daily. Those randomized to meto-
prolol began with 6.25 mg twice daily. Patients were
reassessed weekly. Doses were doubled if there was no
clinical evidence of worsening CHF, heart rate was 65
beats/min and systolic BP was85 mm Hg. Target dosages
were carvedilol 25 mg twice daily or metoprolol 50 mg twice
daily. Once these were achieved, patients were reassessed
monthly in clinic. The assigned dose was taken on the
morning of the second study.
Data analysis. The MSNA was expressed as burst fre-
quency (bursts/min), burst incidence (bursts/100 cardiac
cycles) and integrated nerve activity (units; the product of
burst frequency and mean burst amplitude). For the purpose
of between-subject comparisons, the latter was normalized,
for each subject, against the maximum burst amplitude
recorded during the 9-min baseline period. Calf vascular
resistance (CVR) was calculated as the quotient of mean
arterial pressure and the average of four to six calf blood flow
measurements, with CVC the inverse of CVR. All analyses
were performed and calculated prior to unblinding of the
principal investigators.
Frequency domain analysis was performed using previ-
ously published methods (20). Both MSNA and continuous
BP signals were submitted to fast Fourier transformation.
The following conventional frequency bands were applied to
both signals: very low frequency (VLF), 0.0098 to 0.05 Hz;
low frequency (LF), 0.05 to 0.15 Hz; and high frequency
(HF), 0.15 to 0.5 Hz. To calculate the gain of the transfer
function from MSNA to BP, power in the cross-spectrum
of MSNA and BP was divided by power in the autospec-
trum of MSNA. Gain and coherence values presented are
those calculated as average values across entire prescribed
frequency bands (20).
Statistical analysis. Values are expressed as means  SE.
Physiologic and pharmacologic characteristics of the two
groups of subjects were compared by the unpaired t test and
the Fisher exact test. When data were distributed normally,
paired t tests were used for within-group comparisons of
pre- and four-month beta-blockade values. The Wilcoxon
rank-sum test was applied whenever tests of normality
failed. Two-way analysis of variance (ANOVA) was used
for between-group comparisons of baseline data before and
with beta-blockade. Two-way ANOVA with repeated mea-
sures was used to evaluate the effect of each drug on
Abbreviations and Acronyms
ANOVA  analysis of variance
BP  blood pressure
CBF  calf blood flow
CHF  congestive heart failure
CVC  calf vascular conductance
CVR  calf vascular resistance
ECG  electrocardiogram
HF  high frequency
LF  low frequency
MSNA  muscle sympathetic nerve activity
VLF  very low frequency
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responses to handgrip exercise. A p value 0.05 was
required for statistical significance.
RESULTS
Subjects. Thirty-six patients with a mean age of 54.6 1.8
years and with a mean left ventricular ejection fraction of
19  1% were recruited. Of these, 18 were randomized to
each drug. High-quality mean voltage neurograms could
not be obtained in four subjects (two per group); they were
not retested. One carvedilol patient died suddenly four
weeks after randomization. One patient in the metoprolol
group was withdrawn owing to poor drug compliance. Five
(one carvedilol and four metoprolol) patients refused re-
study. The remaining 25 patients (14 in the carvedilol group
and 11 in the metoprolol group) participated in both study
sessions. However, high-quality MSNA could not be ob-
tained during the second study in two subjects (one assigned
carvedilol and one metoprolol) and CBF could not be
measured accurately in two subjects allocated to carvedilol.
Thus, paired analysis of MSNA was possible in 13
carvedilol- and 10 metoprolol-treated subjects, and paired
calf hemodynamics at rest were available for 11 patients in
the carvedilol group and 10 in the metoprolol group.
Of the 23 subjects who completed the study, 18 partici-
pated in the handgrip exercise (10 carvedilol and 8 meto-
prolol). Paired measurements of CBF were available for
comparison of calf vascular responses to handgrip exercise
before and after beta-blockade in eight patients in each
group.
Effect of beta-blockade. No significant differences existed
in age, gender or other baseline characteristics between
carvedilol- and metoprolol-treated subjects (Table 1). Un-
derlying medical therapy for CHF was stable throughout
the study. At the time of the second study the mean doses
prescribed were 43  4 mg/day of carvedilol and 65 
10 mg/day of metoprolol.
Table 2 summarizes the effect of four months of beta-
blockade on systemic and calf hemodynamics and on
MSNA. Neither drug altered BP, but both lowered heart
rate (p  0.0001, carvedilol; p  0.017, metoprolol). No
significant difference was seen between this effect of carve-
dilol and metoprolol on heart rate. Carvedilol did not alter
sympathetic vasoconstrictor traffic to the calf: MSNA burst
frequency, burst incidence and integrated activity were
unchanged. Metoprolol tended to decrease MSNA burst
frequency and integrated activity (p  0.07) but not burst
incidence. Neither drug altered resting CBF, resistance or
conductance.
Response to handgrip exercise. Handgrip increased BP
and heart rate significantly; four months of beta-
adrenoceptor blockade had no effect on these responses to
exercise (Table 3). Before carvedilol, handgrip increased
Table 1. Prerandomization Characteristics of Those Patients
Who Completed the Study Protocol
Carvedilol
(n  13)
Metoprolol
(n  10)
Age 56  3 49  3
Gender (M/F) 12/1 9/1
Body weight (kg) 91  5 91  6
NYHA functional class (II/III) 11/2 8/2
LVEF (%) 21  2 19  3
Cause of CHF
DCM 6 7
ICM 7 3
Background medications
ACE inhibitor 13 9
AT1 blocker 0 1
Diuretics 8 10
Digoxin 6 5
Values represent either absolute number or means  SE.
ACE  angiotensin-converting enzyme; AT1  angiotensin II type 1 receptor;
CHF congestive heart failure; DCM idiopathic dilated cardiomyopathy; ICM
ischemic cardiomyopathy; LVEF  left ventricular ejection fraction; NYHA  New
York Heart Association.
Table 2. Effects of Beta-Blockade on Resting Hemodynamics and MSNA
Carvedilol (n  13) Metoprolol (n  10)
Baseline 4 Months Baseline 4 Months
Systemic hemodynamics
SBP, mm Hg 126  7 121  8 116  8 121  8
DBP, mm Hg 74  3 69  3 68  3 67  4
MAP, mm Hg 92  4 86  5 84  4 85  5
HR, beats/min 76  3 62  2* 72  5 62  3†
Calf hemodynamics‡
CBF, ml/min/100 ml 1.5  0.2 1.6  0.3 1.7  0.3 1.7  0.3
CVR, resistance U 76.4  12.0 80.4  15.7 58.9  8.5 65.6  11.5
CVC, U  103 16  2 18  3 20  2 20  4
MSNA
MSNA/min 48.2  4.0 42.2  4.1 50.0  4.3 39.7  4.5
MSNA/100 heart beats 62.1  4.9 66.7  5.8 69.6  5.2 62.9  4.7
U  102§ 20.2  2.4 19.0  2.0 22.2  3.1 15.3  2.5
*p  0.01 compared with baseline values prior to carvedilol; †p  0.05 compared with baseline values prior to metoprolol;
‡carvedilol group, n  11; §metoprolol group, n  9. Values are means  SE.
CBF  calf blood flow; CVC  calf vascular conductance; CVR  calf vascular resistance; DBP  diastolic blood pressure;
HR  heart rate; MAP  mean arterial pressure; MSNA  muscle sympathetic nerve activity; SBP  systolic blood pressure;
U  units.
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MSNA (p  0.01, p  0.04, p  0.01 for burst frequency,
burst incidence, and integrated activity, respectively) and
CVR (p  0.007), and decreased CVC (p  0.01). As can
be seen in Figure 1, MSNA increased in all subjects
(including four with diabetes). Carvedilol had no effect on
the reflex sympathoneural response to isometric exercise, or
on the calf hemodynamic response to this vasoconstrictor
stimulus. Metoprolol tended to decrease integrated MSNA
both before and during handgrip (p  0.051), but not burst
frequency (p  0.15) or burst incidence (p  0.76), and
there was no interaction term between treatment and
handgrip responses.
Gain of the neuroeffector transfer function. The transfer
function from MSNA to BP can be considered a represen-
tation of signal transduction at the level of the resistance
vessels in muscular beds (20). Transfer function analysis was
possible in 13 patients in the carvedilol group and 8 patients
in the metoprolol group. Figure 2 illustrates the gain of the
transfer function from MSNA to BP before and after four
months of carvedilol. As documented previously, this gain is
highest within the VLF range, with a progressive reduction
from VLF to LF to HF bands (20). After four months of
carvedilol, there was no change in either gain or coherence
in any frequency band (gain: from 0.55  0.08 to 0.71 
0.08 mm Hg/U in VLF, p  0.120; from 0.38  0.06 to
0.46  0.11 in LF, p  0.457; from 0.19  0.03 to 0.24 
0.04 mm Hg/U in HF, p  0.231). After four months of
metoprolol, VLF and LF gain increased (both p  0.05),
whereas HF gain was unchanged. Both VLF and HF
coherence also increased (both p  0.05). However, two-
way ANOVA indicated no between-group difference with
regard to these values for gain and coherence.
DISCUSSION
Major findings. In addition to augmenting ventricular
function, the proven benefits of long-term beta-blockade for
patients with CHF now include reductions in mortality,
morbidity and need for hospitalization. Carvedilol differs
from metoprolol as it is also an alpha1- and a beta2-receptor
antagonist. Whether its acute effect on alpha1-adrenoceptors
persists during long-term therapy of CHF is uncertain. In
the present study, carvedilol did not increase CVC at rest,
did not attenuate the reflex vasoconstrictor response to
increased sympathetic outflow to the calf elicited by hand-
grip exercise and had no effect on the gain of the transfer
function between the variability of MSNA and the variabil-
ity of BP, a marker of neuroeffector transduction. Moreover,
there was no significant difference between responses to
carvedilol and responses to metoprolol with respect to any of
these variables.
Effect of beta-blockade on calf hemodynamics. There
was no evidence for a functionally important effect of
alpha1-adrenoceptor blockade with carvedilol on CVR or
CVC under resting conditions. Calf vasodilation after
long-term therapy could arise from a number of factors,Ta
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including a reduction in sympathetic nerve traffic to skeletal
muscle with improvement in clinical status, blockade of
alpha1-receptors accessible to norepinephrine released from
calf sympathetic nerve endings, decreased interstitial fluid or
vascular remodeling.
In hypertensive subjects, Svensson et al. (21) were unable
to detect any change in CVR after six months of metopro-
lol. Wallin et al. (22) observed reductions in both BP and
MSNA in hypertensive subjects after four months of mono-
therapy with metoprolol (mean dose 187.5 mg/day). Be-
cause the decline in BP should have elicited a baroreflex-
mediated increase in MSNA, this reduction appeared to
arise from a central sympathoinhibitory action of this
lipophilic beta1-adrenergic antagonist (22). Calf vascular
hemodynamics were not obtained. In a previous study of
patients with dilated cardiomyopathy, we observed a 50%
reduction in sympathetic outflow to calf muscle and a
corresponding 62% decrease in CVR after an average of 20
months of treatment with metoprolol (19)—an observation
also consistent with a central neural action. However, in the
present analysis, neither drug (after four months) signifi-
cantly affected MSNA or resistance in the calf, the vascular
bed distal to the recording electrode.
Muscle sympathetic nerve activity in CHF, recorded at
rest, is inversely related to peak oxygen uptake during
bicycle exercise (23). Exercise evokes a further increase in
MSNA. This exercise pressor reflex is activated at lower
workload, and is of greater magnitude in those with mod-
erate to severe left ventricular systolic dysfunction than in
age-matched healthy subjects. Patients with the lowest peak
oxygen uptake achieve the highest MSNA during exercise
(24). Augmentation of neurogenic vasoconstriction in skel-
etal muscle may limit further exercise capacity in CHF.
Conversely, peripheral alpha1-antagonism could augment
skeletal muscle blood flow and improve exercise perfor-
mance. In young healthy subjects, both MSNA and CVR
are tightly coupled during isometric exercise (25). Neuro-
genic vasoconstriction, evoked by exercise or coronary isch-
emia, can be blocked by intra-arterial infusion of alpha1-
adrenoceptor antagonists (26, 27). However, in the present
study, carvedilol did not alter the reflex increase in MSNA,
or the alpha1-adrenoceptor–mediated calf vasoconstrictor
Figure 1. Effects of carvedilol on muscle sympathetic nerve activity (MSNA) (A, n 10) and calf hemodynamics (B and C, n 8) in response to handgrip
(HG) exercise. Before treatment, HG significantly increased MSNA and calf vascular resistance (CVR), and significantly decreased calf vascular
conductance (CVC). Carvedilol had no effect on the reflex sympathoneural response to HG, or on calf hemodynamic responses to this vasoconstrictor
stimulus. Individual data and means  SE values are expressed. *p  0.01 compared with control values; †p  0.05 compared with control values.
Figure 2. Gain of the transfer function from muscle sympathetic nerve
activity (MSNA) to blood pressure (BP) before and four months after
carvedilol treatment (n  13). Carvedilol did not alter neuroeffector
transfer function gain in any frequency band. Values are means  SE.
Open bars  before treatment; solid bars  after four months treatment.
Very low frequency (VLF)  0–0.05 Hz; low frequency (LF) 
0.05–0.15 Hz; high frequency (HF)  0.15–0.5 Hz.
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response induced by handgrip exercise; before treatment,
MSNA burst frequency and CVR increased by 19% and by
24%, respectively. After four months of treatment, MSNA
and CVR increased by 20% and by 30%, respectively.
This lack of evidence for alpha1-antagonism over the long
term is consistent with previous experience with other
alpha1-blockers, prazosin and doxazosin, in CHF. We did
not test for the presence of acute alpha1-blocking effects of
carvedilol, which might allow for the initial tolerance of this
nonspecific beta-blocker. However, hemodynamic re-
sponses to acute administration of prazosin dissipate rapidly
(28). Tolerance to doxazosin develops during long-term
CHF treatment, even when combined with beta-blockade
(29). When added to a background regimen of digoxin and
diuretics, prazosin had no long-term effect on left ventric-
ular function or on mortality (30).
Effects of carvedilol on neuroeffector transfer function.
The transfer function from sympathetic nerve activity to
arterial resistance behaves as a low-pass filter, in that signal
transduction at the level of the neuroarterial junction di-
minishes at higher frequencies (31). Cross-spectral analysis
in humans indicates that the gain of the transfer function
from MSNA to BP is also highest in the VLF range,
intermediate in the LF range and lowest in the HF spectral
band (20). Transfer function gain within the VLF and LF
ranges is significantly lower in patients with CHF than in
healthy control subjects. We reasoned that if carvedilol did
block the postjunctional action of neurally released norepi-
nephrine at the level of the alpha1-adrenoreceptor, modu-
lation of vascular smooth muscle responses to changes in
sympathetic outflow would have been blunted. However,
carvedilol had no effect on the gain or on the coherence of
this neuroeffector transfer function, providing no evidence
for alpha1-antagonism. The results of this transfer function
analysis (from MSNA to BP) might be confounded by the
“closed-circuit” nature of the baroreflex. However, the
frequency response characteristics of the arterial barorecep-
tors cause the BP3MSNA component of this loop to act
as a high-pass filter (20,32) that opens lower frequencies to
study.
Conclusions. After four months of therapy, neither carve-
dilol nor metoprolol had any effect on calf hemodynamics,
either at rest, or in response to neurogenic vasoconstriction
assessed by handgrip exercise. The gain of the transfer
function relating oscillations in MSNA to oscillations in BP
was unchanged after four months of carvedilol. Therefore,
the peripheral alpha1-blocking property of carvedilol does
not appear to be functionally important during long-term
treatment of CHF.
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